Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E3 | Q9Y5X4 | 3/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027443 | 0.91 | NR2E3 (0.49) | NR2E3KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6886575 | 0.90 | NPC1 (0.43) | NR2E3KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6883824 | 0.86 | KMT2A (0.53) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL6885314 | 0.86 | NPC1 (0.53) | NR2E3KMT2ANPC1RAB9ABCAT2 | |
| SCHEMBL6886834 | 0.84 | KMT2A (0.53) | MEN1KMT2AKDM4ENPC1PKM | |
| SCHEMBL6886236 | 0.83 | KDM4E (0.44) | NR2E3KMT2AKDM4ENPC1MAPT | |
| SCHEMBL6028312 | 0.83 | RAB9A (0.52) | KDM4ENPC1MAPTRAB9A | |
| SCHEMBL6028319 | 0.82 | PTPN1 (0.54) | KDM4ENPC1RAB9A | |
| SCHEMBL6029160 | 0.82 | PTPN1 (0.54) | KDM4ENPC1RAB9A | |
| SCHEMBL6027809 | 0.82 | RAB9A (0.55) | NR2E3KMT2AKDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | NR2E3 3895/4885KCNQ3 3602/4885KCNQ2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.